Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 254-257

  Crettol, S ^a   De Leon, J ^b   Hiemke, C ^c   Eap, C B ^a,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Eastern State Hospital   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; DRUG MONITORING; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 84894473210     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.221     Document Type: Article

References (5)

1. de Leon, J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res. 59, 81-89 (2009).
2. Eap, C.B. et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81, 719-728 (2007).
3. Hiemke, C. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011).
4. Chen, P. et al.; Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011).
5. Athanasiou, M.C. et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 72, 458-463 (2011).